The Assistance Fund, an independent and charitable foundation, announced that it has launched a new copay assistance program to…
Articles by Joana Carvalho, PhD
A pulmonary rehabilitation program lowers the risk of mortality among patients with idiopathic pulmonary fibrosis after lung transplant, as…
A treatment algorithm based on high-flow nasal cannula oxygen therapy reduces short-term mortality of people with idiopathic pulmonary…
Patients with idiopathic pulmonary fibrosis (IPF) produce a large amount of abnormal airway immune cells lacking an iron receptor…
Contrary to what has been suggested, antacid therapies may not change survival or disease progression rates among people with…
Paragonix Technologies and the Lung Transplant Foundation (LTF) are expanding their collaboration to drive the development of several technologies…
Many patients with idiopathic pulmonary fibrosis (IPF) who are switching from Esbriet (pirfenidone) to Ofev (nintedanib) discontinue treatment,…
Elderly patients with idiopathic pulmonary fibrosis (IPF) have high morbidity and mortality, and experience a variety of comorbidities both before…
Blocking the platelet-derived growth factor receptor-beta (PDGFR-β) prevents lung fibrosis in a mice model of pulmonary fibrosis, a study says.
Researchers from the Medical University of South Carolina (MUSC) may have found a new therapeutic target for the treatment of…